Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Bremelanotide
PT-141 (Bremelanotide) is a synthetic melanocortin receptor agonist originally developed from Melanotan II. It has been FDA-approved for treatment of hypoactive sexual desire disorder in premenopausal women.
Acts on melanocortin-4 receptors (MC4R) in the central nervous system to modulate sexual arousal through neural pathways rather than peripheral vascular effects.
FDA-approved in 2019 under the brand name Vyleesi for HSDD in premenopausal women. Clinical trials demonstrated statistically significant increases in sexual desire and decreases in distress. Off-label use in men has shown mixed results.
Typical Dose
2mg
Range
1-2mg
Frequency
As needed (subcutaneous)
Route
SubQ
Duration
As needed
Reconstitution
10mg vial + 2mL bacteriostatic water = 5,000mcg/mL
Notes
FDA-approved dose is 1.75 mg SubQ. Not recommended for use more than once within 24 hours or more than 8 times per month. Blood pressure should be monitored.
These biomarkers are commonly tracked to assess response and safety. Run baseline labs before starting, mid-cycle labs halfway through, and post-cycle labs 1–2 weeks after the final dose.
Build a protocol with PT-141, schedule blood work for key biomarkers, and track your results.
Build Protocol with PT-141This platform provides informational tools only, not medical advice. This information is for educational purposes only. Consult a licensed provider.
Disclosed Labs